TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improved Time in Therapeutic Range With Patient Self-Testing of Their INR Compared to Usual Care: A Randomized Controlled Trial
Brief Summary: Patients who receive a mechanical heart valve to replace a diseased heart valve must take an anticoagulation medicine the rest of their lives, and monitor their level of anticoagulation. Until recently, the testing of the level of anticoagulation was performed at medical laboratories or hospitals.

The purpose of this study is to see if patients who test their level of anticoagulation by themselves at home and then call their doctor with the result have better control of their anticoagulation as compared to patients whose anticoagulation is checked only by their physician.


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Weekly patient self-testing of prothrombin time | Arm Label: Arm 2; Type: OTHER; Interventions: Other: High quality anticoagulation management (HQACM) with conventional monthly testing | Intervention Type: PROCEDURE; Name: Weekly patient self-testing of prothrombin time; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: High quality anticoagulation management (HQACM) with conventional monthly testing; Assigned to Arm(s): Arm 2
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-management; Type: EXPERIMENTAL; Interventions: Other: Self-monitoring and adjustment of oral anticoagulation | Intervention Type: OTHER; Name: Self-monitoring and adjustment of oral anticoagulation; Assigned to Arm(s): Self-management
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Patient Self Testing; Type: ACTIVE_COMPARATOR; Interventions: Device: INRatio monitor by Hemosense | Intervention Type: DEVICE; Name: INRatio monitor by Hemosense; Assigned to Arm(s): Patient Self Testing | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: Warfarin | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Group B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rivastigmine for Delirium in Intensive Care Patients, a Double-blind, Randomized Placebo-controlled add-on Trial
Brief Summary: Delirium in Intensive Care (IC) patients is a frequent disorder. The aim of this study is to investigate whether treatment of delirium in the ICU with rivastigmine added to haloperidol shortens the duration of delirium in comparison to placebo added to the treatment with haloperidol.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rivastigmine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivastigmine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group
C: Arm Label: Early PT OT; Type: EXPERIMENTAL; Interventions: Procedure: early PT OT | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: early PT OT; Assigned to Arm(s): Early PT OT
D: Arm Label: Dexmedetomidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Saline placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline placebo | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Saline placebo; Assigned to Arm(s): Saline placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rivastigmine for Delirium in Intensive Care Patients, a Double-blind, Randomized Placebo-controlled add-on Trial
Brief Summary: Delirium in Intensive Care (IC) patients is a frequent disorder. The aim of this study is to investigate whether treatment of delirium in the ICU with rivastigmine added to haloperidol shortens the duration of delirium in comparison to placebo added to the treatment with haloperidol.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rivastigmine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivastigmine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Xenon; Type: EXPERIMENTAL; Interventions: Drug: Xenon | Arm Label: Sevoflurane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevoflurane | Intervention Type: DRUG; Name: Xenon; Assigned to Arm(s): Xenon | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): Sevoflurane
C: Arm Label: Investigational medicinal product; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): Investigational medicinal product | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group
D: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Treatment | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week, Open Label, Multicenter, Titration Study, With a 12 Month Extension, to Determine the Optimal Titration Regimen for SBR759, Compared to Sevelamer HCl, in Lowering Serum Phosphate Levels in Asian Patients With Chronic Kidney Disease on Hemodialysis
Brief Summary: This study will determine the titration regimen for SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Asian Chronic Kidney Disease patients on hemodialysis


Options:
A: Arm Label: Renal Function Group #1; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #2; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #3; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #4; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #5; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #6; Type: N/A; Interventions: N/A | Arm Label: Renal Function Group #7; Type: N/A; Interventions: N/A
B: Arm Label: Lanthanum carbonate; Type: EXPERIMENTAL; Interventions: Drug: Lanthanum carbonate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lanthanum carbonate; Assigned to Arm(s): Lanthanum carbonate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SBR759 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer HCl | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Sevelamer HCl | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer HCl | Intervention Type: DRUG; Name: SBR759; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sevelamer HCl; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Sevelamer HCl; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Sevelamer HCl; Assigned to Arm(s): 2
D: Arm Label: ASP1585 dose #1; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: ASP1585 dose #2; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: ASP1585 dose #3; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sevelamer hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer hydrochloride | Intervention Type: DRUG; Name: ASP1585; Assigned to Arm(s): ASP1585 dose #1, ASP1585 dose #2, ASP1585 dose #3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sevelamer hydrochloride; Assigned to Arm(s): Sevelamer hydrochloride

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Using Video Images in Dementia
Brief Summary: BACKGROUND: Advance care planning (ACP) is the process in which patients plan for future medical care under circumstances of impaired decision-making. Video is an underutilized medium that can assist clinicians in discussions of future health states, such as the state of advanced dementia. Video may enable patients to visualize the future by concisely providing complex information vital for ACP. This study will examine whether the use of video could facilitate a more comprehensive understanding of advanced dementia and inform clinician-patient discussions about the level of care a patient would want in the event of advanced dementia.

RESEARCH PLAN: We propose to conduct a randomized trial studying ACP for 200 elderly subjects using a video depiction of a patient with dementia compared to the traditional verbal narrative. Specific aims 1 and 2 assess the effect of a video of advanced dementia on the clinical decision making of elderly subjects compared to the traditional verbal narrative.


Options:
A: Arm Label: Vascular Access Patient Decision Aid; Type: EXPERIMENTAL; Interventions: Behavioral: Vascular Access Decision Aid | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Vascular Access Decision Aid; Assigned to Arm(s): Vascular Access Patient Decision Aid
B: Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: evaluation of cancer risk factors; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fecal occult blood test; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: screening colonoscopy; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: OTHER; Interventions: Behavioral: Cognitive Behavioral Intervention | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Office System Redesign Intervention | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Office System Redesign Intervention; Assigned to Arm(s): 2
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: video | Intervention Type: OTHER; Name: video; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women
Brief Summary: The goal of this three-armed randomized controlled trial is to establish the relative roles of treatment of hyperandrogenism versus obesity (as the largest modifiable factor contributing to insulin resistance) in treating infertility and improving pregnancy outcomes among obese PCOS women. The investigators hypothesize that the key to restoring ovulation leading to live birth is to correct hyperandrogenism with oral contraceptive pills, but the key to avoiding later pregnancy complications is to improve insulin sensitivity with weight loss.


Options:
A: Arm Label: Lifestyle intervention; Type: ACTIVE_COMPARATOR; Interventions: Drug: Orlistat/Meal Replacement/Lifestyle Modification | Arm Label: Oral Contraceptives (OCP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Loestrin 1/20 | Arm Label: Lifestyle/OCP Combined; Type: ACTIVE_COMPARATOR; Interventions: Drug: Combination of treatments | Intervention Type: DRUG; Name: Orlistat/Meal Replacement/Lifestyle Modification; Assigned to Arm(s): Lifestyle intervention | Intervention Type: DRUG; Name: Loestrin 1/20; Assigned to Arm(s): Oral Contraceptives (OCP) | Intervention Type: DRUG; Name: Combination of treatments; Assigned to Arm(s): Lifestyle/OCP Combined
B: Arm Label: strength training; Type: EXPERIMENTAL; Interventions: Behavioral: strength training | Arm Label: interval training; Type: EXPERIMENTAL; Interventions: Behavioral: interval training | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: strength training; Assigned to Arm(s): strength training | Intervention Type: BEHAVIORAL; Name: interval training; Assigned to Arm(s): interval training
C: Intervention Type: BEHAVIORAL; Name: Structured exercise training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Hypocaloric hyperproteic diet; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: obesity intervention; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Cluster Randomized Controlled Evaluation of the Impact of Zinc and / or Micronutrient Supplementation on Intestinal Flora, Diarrheal Disease Burden, Intestinal Mucosal Integrity and Growth Among Cohorts of Children in Pakistan
Brief Summary: Information on the mechanisms of zinc is still in developing phase. Ecological and biological implications of long term zinc supplementation at population level requires assessment. The trial aims to assess the impact of routine supplementation of zinc among young growing children and evaluate its impact on intestinal microbial flora and relationship with gut mucosa integrity and co-morbidities.


Options:
A: Arm Label: A, 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: folic acid | Arm Label: A, 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: folic acid plus iron | Arm Label: A, 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: supplements with multiple vitamins and minerals | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): A, 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid plus iron; Assigned to Arm(s): A, 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: supplements with multiple vitamins and minerals; Assigned to Arm(s): A, 3
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Other: Nutritional Counselling and Education | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Supplementation without Zinc | Arm Label: C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Supplementation with Zinc | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Supplementation without Zinc; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Supplementation with Zinc; Assigned to Arm(s): C | Intervention Type: OTHER; Name: Nutritional Counselling and Education; Assigned to Arm(s): A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ferrous fumarate (iron), Dietary Supplement: folic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Ferrous fumarate (iron); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: folic acid; Assigned to Arm(s): 1, 2
D: Arm Label: Pregnant Women; Type: N/A; Interventions: Drug: Traditional Tablet, Drug: Chewable tablets, Drug: Unflavoured Powder, Drug: Flavoured Powder | Intervention Type: DRUG; Name: Traditional Tablet; Assigned to Arm(s): Pregnant Women | Intervention Type: DRUG; Name: Chewable tablets; Assigned to Arm(s): Pregnant Women | Intervention Type: DRUG; Name: Unflavoured Powder; Assigned to Arm(s): Pregnant Women | Intervention Type: DRUG; Name: Flavoured Powder; Assigned to Arm(s): Pregnant Women

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Cluster Randomized Controlled Evaluation of the Impact of Zinc and / or Micronutrient Supplementation on Intestinal Flora, Diarrheal Disease Burden, Intestinal Mucosal Integrity and Growth Among Cohorts of Children in Pakistan
Brief Summary: Information on the mechanisms of zinc is still in developing phase. Ecological and biological implications of long term zinc supplementation at population level requires assessment. The trial aims to assess the impact of routine supplementation of zinc among young growing children and evaluate its impact on intestinal microbial flora and relationship with gut mucosa integrity and co-morbidities.


Options:
A: Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: zinc sulphate dietary supplement; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iron sulphate-folic acid dietary supplement; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: zinc | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: zinc | Intervention Type: DRUG; Name: zinc; Assigned to Arm(s): 1, 2
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Other: Nutritional Counselling and Education | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Supplementation without Zinc | Arm Label: C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Supplementation with Zinc | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Supplementation without Zinc; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Supplementation with Zinc; Assigned to Arm(s): C | Intervention Type: OTHER; Name: Nutritional Counselling and Education; Assigned to Arm(s): A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Brief Summary: The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia.

The trial was designed into 4 treatment phases. Phase 1 was designed to allow for a patient to be converted from their current antipsychotic treatment to oral non-generic aripiprazole monotherapy (oral conversion phase from 4 to 6 weeks). During Phase 2, the patient was stabilized on oral non-generic aripiprazole monotherapy (oral stabilization phase from a minimum of 4 weeks to a maximum of 12 weeks). Once the patient was stabilized in Phase 2, they entered Phase 3, the single-blind intramuscular (IM) depot aripiprazole stabilization phase. The goal of the phase was to stabilize the patient on the IM depot aripiprazole formulation for a minimum of 12 weeks to a maximum of 36 weeks. When the patient was stabilized, they were eligible to be randomized into the double-blind IM depot maintenance phase (Phase 4). During Phase 4, the patient was assessed for exacerbation of psychotic symptoms and/or impending relapse for up to 52 weeks.


Options:
A: Arm Label: Lurasidone Open-Label Arm A; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Arm Label: Lurasidone Open-Label Arm B; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Arm Label: Lurasidone Open-Label Arm C; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone HCl | Intervention Type: DRUG; Name: Lurasidone HCl; Assigned to Arm(s): Lurasidone Open-Label Arm A, Lurasidone Open-Label Arm B, Lurasidone Open-Label Arm C
B: Arm Label: Quetiapine or Risperidone + Aripiprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine or Risperidone + Aripiprazole | Arm Label: Quetiapine or Risperidone + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Quetiapine or Risperidone + placebo | Intervention Type: DRUG; Name: Quetiapine or Risperidone + Aripiprazole; Assigned to Arm(s): Quetiapine or Risperidone + Aripiprazole | Intervention Type: DRUG; Name: Quetiapine or Risperidone + placebo; Assigned to Arm(s): Quetiapine or Risperidone + placebo
C: Arm Label: Aripiprazole depot; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot | Arm Label: Placebo depot; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo depot | Intervention Type: DRUG; Name: Aripiprazole depot; Assigned to Arm(s): Aripiprazole depot | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Placebo depot
D: Arm Label: sulpiride plus amisulpride; Type: EXPERIMENTAL; Interventions: Drug: full-dose amisulpride | Arm Label: full-dose amisulpride; Type: ACTIVE_COMPARATOR; Interventions: Drug: full-dose amisulpride | Intervention Type: DRUG; Name: full-dose amisulpride; Assigned to Arm(s): full-dose amisulpride, sulpiride plus amisulpride

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
Brief Summary: The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia.

The trial was designed into 4 treatment phases. Phase 1 was designed to allow for a patient to be converted from their current antipsychotic treatment to oral non-generic aripiprazole monotherapy (oral conversion phase from 4 to 6 weeks). During Phase 2, the patient was stabilized on oral non-generic aripiprazole monotherapy (oral stabilization phase from a minimum of 4 weeks to a maximum of 12 weeks). Once the patient was stabilized in Phase 2, they entered Phase 3, the single-blind intramuscular (IM) depot aripiprazole stabilization phase. The goal of the phase was to stabilize the patient on the IM depot aripiprazole formulation for a minimum of 12 weeks to a maximum of 36 weeks. When the patient was stabilized, they were eligible to be randomized into the double-blind IM depot maintenance phase (Phase 4). During Phase 4, the patient was assessed for exacerbation of psychotic symptoms and/or impending relapse for up to 52 weeks.


Options:
A: Arm Label: Aripiprazole depot 300 or 400 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 300 or 400 mg, Drug: Placebo tablets | Arm Label: Aripiprazole 10-30 mg orally; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 10-30 mg orally, Drug: Placebo depot | Arm Label: Aripiprazole depot 25 or 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 25 or 50 mg, Drug: Placebo tablets | Intervention Type: DRUG; Name: Aripiprazole depot 300 or 400 mg; Assigned to Arm(s): Aripiprazole depot 300 or 400 mg | Intervention Type: DRUG; Name: Aripiprazole 10-30 mg orally; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Aripiprazole depot 25 or 50 mg; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Placebo tablets; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg, Aripiprazole depot 300 or 400 mg
B: Intervention Type: DRUG; Name: Intramuscular Olanzapine Depot; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Oral Olanzapine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A
D: Arm Label: Aripiprazole depot; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot | Arm Label: Placebo depot; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo depot | Intervention Type: DRUG; Name: Aripiprazole depot; Assigned to Arm(s): Aripiprazole depot | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Placebo depot

Answer: D